Genmab to Acquire Merus in $8 Billion Deal to Bolster Cancer Pipeline
Genmab A/S and Merus N.V. announced a definitive agreement under which Genmab will acquire all outstanding shares of Merus for $97.00 per share in an all-cash transaction valued at…
Read More...
Read More...
